^
BIOMARKER:

PD-L1 expression + EGFR mutation

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule, EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3ms
PD-L1 Expression Predicts Prognosis in Completely Resected NSCLC Patients with an EGFR Mutation (IASLC-WCLC 2022)
PD-L1 high expression was associated with poor DFS in completely resected NSCLCs with EGFR mutation, especially in those treated with adjuvant targeted therapy. Figure1. Our study (A) depicted the association between PD-L1 expression (B) or PD-L1 high expression (C, D) and DFS in the completely resected EGFR mutation NSCLC patients.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR expression • EGFR mutation + PD-L1 expression • PD-L1 expression + EGFR mutation
7ms
A prediction model integrated genomic alterations and immune signatures of tumor immune microenvironment for early recurrence of stage I NSCLC after curative resection. (PubMed, Transl Lung Cancer Res)
High TMS and low IS were both poor prognostic factors for recurrence in stage I NSCLC. The integrated recurrence-model helps identify patients with high recurrence risk, which provides evidence for future research about perioperative treatment.
Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • MUC4 (Mucin 4, Cell Surface Associated)
|
PD-L1 expression • TMB-H • EGFR mutation • EGFR expression • PD-L1 expression + EGFR mutation
|
Immunoscore®
8ms
The relationship between PD-L1 expression and tumor driver gene mutations and survival in non small cell lung carcinoma. (PubMed, Pol J Pathol)
These results suggested that PD-L1 expression is not an independent risk factor for survival of patients with NSCLC. Because of mutual complementarities of PD-L1 expression and EGFR mutation in NSCLC, both should be simultaneously detected for the patients to achieve eligible treatments.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • EGFR mutation • EGFR expression • MET mutation • MET expression • PD-L1 expression + EGFR mutation
9ms
Deep Learning to Predict EGFR Mutation and PD-L1 Expression Status in Non-Small-Cell Lung Cancer on Computed Tomography Images. (PubMed, J Oncol)
Additionally, the combination of deep learning features with clinical features demonstrated great stratification capabilities in the prognostic model. Our team would continue to explore the application of imaging markers for treatment selection of lung cancer patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • EGFR mutation • EGFR expression • PD-L1 expression + EGFR mutation
11ms
PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC. (PubMed, Sci Rep)
The high PD-L1 (≥ 50%) expression was negatively associated with Ex21. These findings may help identify NSCLC patients with an increased risk of postoperative recurrence.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • EGFR mutation • EGFR L858R • EGFR expression • PD-L1 expression + EGFR mutation
1year
Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations (PubMed, Zhongguo Fei Ai Za Zhi)
According to the Chinese Expert Consensus on Standards of PD-L1 immunohistochemistry testing for NSCLC, we tested the PD-L1 expression in NSCLC and then the dominant population of anti-PD-1/PD-L1 treatment was screened out. Patients with EGFR mutation were also detected and EGFR mutation was negatively correlated with the expression of PD-1 and PD-L1 as well. On the basis of PD-L1 expression and EGFR mutation status, it may benefit NSCLC patients from individualized treatment. Meanwhile, patients who were under the age of 65, adenocarcinoma, well-differentiated and moderately-differentiated, hypo expression of PD-L1 have a relatively good prognosis, to provide reference for the prognosis evaluation of NSCLC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • EGFR mutation • EGFR expression • PD-1 expression • PD-L1 expression + EGFR mutation
over1year
Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma. (PubMed, Transl Lung Cancer Res)
B3GNT3 is associated with poor prognosis in lung adenocarcinoma patients. Collectively, these findings may offer new insight into enhancing immune therapy efficacy for lung adenocarcinoma patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • EGFR mutation • PD-L1 expression + EGFR mutation
over1year
The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer. (PubMed, Front Oncol)
The common grades 1-2 adverse events were fatigue 10/22 (45.5%), decreased appetite 9/22 (40.9%), hypertension 10/22 (45.5%); the common grades 3-4 adverse events were hypertension 2/22 (9.1%) and mouth ulceration 2/22 (9.1%). Anlotinib combined with PD-1 mAb showed promising efficacy in third-line or further-line treatment of NSCLC, and its adverse effects is tolerable.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • EGFR mutation • EGFR expression • PD-L1 expression + EGFR mutation
|
Focus V (anlotinib)